# A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

> **NCT05183360** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 706321
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05183360
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-07
- **Primary completion:** 2022-08-12
- **Final completion:** 2024-08-08
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05183360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05183360, "A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05183360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*